Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03919669 · ClinicalTrials.gov registry record · Phase 2
A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT03919669 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 27 participants.
The verdict
NCT03919669, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a longitudinal, observational study evaluating the imaging characteristics of the tau PET radioligand \[18F\]MK-6240 in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and Healthy Volunteer (HV) subjects. Up to 42 subjects, including approximately 28 MCI/mild AD subjects, up to 5 moderate AD subjects, and 9 similarly aged HV subjects will be consented and screened. Imaging procedures include \[11C\]PiB to evaluate amyloid deposition, \[18F\]MK-6240 PET, and structural MRI. All subjects complete an evaluable baseline \[18F\]MK-6240 PET scan, as well as scans at 6, 12 and 24 months post-baseline. If unable to complete the 6 month, 12 month, or 24 month visit, an 18 month and/or 30 month visit may instead be scheduled, totaling a maximum of four time points.
Interventions
- DRUG All Subjects
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-04-02 |
| Est. Completion | 2022-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03919669
The ClinicalTrials.gov registry entry for NCT03919669 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which All Subjects is the first listed.
NCT03919669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03919669 about?
NCT03919669 is a clinical study titled "A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking". This is a longitudinal, observational study evaluating the imaging characteristics of the tau PET radioligand \[18F\]MK-6240 in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and Healthy Volunteer (HV) subjects. Up to 42 subjects, including approximately 28 MCI/mild AD subjects, up to 5 m...
What is the current status of trial NCT03919669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2019-04-02. Estimated completion is 2022-05-19.
What interventions are being tested in trial NCT03919669?
The interventions under investigation include: All Subjects (DRUG).
Who is sponsoring clinical trial NCT03919669?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.